Prosecution Insights
Prosecution Insights
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (43%) |
| Double-patenting + other | 1 (14%) |
| No statute on record | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEELE, AMBER D | 1 | 59.1% | +9.1% |
| MYERS, CARLA J | 1 | 48.6% | +47.0% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.4% |
| BELYAVSKYI, MICHAIL A | 1 | 63.8% | +27.5% |
| DABKOWSKI, ERINNE R | 1 | 55.8% | +69.0% |
| D' AMBROSIO, THEA | 1 | 55.6% | +56.8% |
| NIEBAUER, RONALD T | 1 | 41.4% | +33.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17252038 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | NIEBAUER, RONALD T | 72d overdue |
| 18001374 | TREATMENT OF DISEASES CHARACTERIZED BY OVEREXPRESSION OF ERYTHROPOIETIN-PRODUCING HEPATOCELLULAR RECEPTOR A2 (EPHA2) | PUTTLITZ, KARL J | 19d overdue |
| 17630747 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | DABKOWSKI, ERINNE R | 6d |
| 18021748 | BICYCLE CONJUGATES SPECIFIC FOR NECTIN-4 AND USES THEREOF | MYERS, CARLA J | 13d |
| 17926454 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 AND USES THEREOF | BELYAVSKYI, MICHAIL A | 15d |
| 17309626 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | D' AMBROSIO, THEA | 34d |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1654 | 2 |
| 1682 | 1 |
| 1646 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18271353 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | STEELE, AMBER D | 1658 | DPOther | Non-Final OA | 63d | Pending | Jul 07, 2023 |
| 18021748 | BICYCLE CONJUGATES SPECIFIC FOR NECTIN-4 AND USES THEREOF | MYERS, CARLA J | 1682 | §103 | Non-Final OA | 13d | Pending | Feb 16, 2023 |
| 18001374 | TREATMENT OF DISEASES CHARACTERIZED BY OVEREXPRESSION OF ERYTHROPOIETIN-PRODUCING HEPATOCELLULAR RECEPTOR A2 (EPHA2) | PUTTLITZ, KARL J | 1646 | §103 | Non-Final OA | 19d overdue | Pending | Dec 09, 2022 |
| 17926454 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 AND USES THEREOF | BELYAVSKYI, MICHAIL A | 1644 | §103 | Final Rejection | 15d | Pending | Nov 18, 2022 |
| 17630747 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | DABKOWSKI, ERINNE R | 1654 | Other | Non-Final OA | 6d | Pending | Jan 27, 2022 |
| 17309626 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | D' AMBROSIO, THEA | 1654 | Other | Final Rejection | 34d | Pending | Jun 11, 2021 |
| 17252038 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | NIEBAUER, RONALD T | 1658 | Other | Non-Final OA | 72d overdue | Pending | Dec 14, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial